NEW YORK (GenomeWeb News) — Certain members of Tripos’ management team may consider buying the firm’s Discovery Research business if bids by Provid Pharmaceuticals or other parties fall through, the company said last week.
 
Tripos made its remarks as the company said that fourth-quarter revenues declined 8 percent as R&D spending fell 35 percent and loss narrowed 46 percent.
 
Total receipts for the three months ended Dec. 31, 2006, fell to $6.7 million from $7.2 million year over year.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.

Mar
13
Sponsored by
Agilent

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.